世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

医薬品受託開発・製造市場:サービス毎(医薬品、生物製剤・バイオロジクス、医薬品有効成分、錠剤、カプセル、非経口、経口液剤)、エンドユーザ毎(医薬品大企業、医薬品中小企業、ジェネリック医薬品企業、CRO) - 2024年までの世界市場予測

Pharmaceutical Contract Development and Manufacturing Market by Service (Pharmaceutical, Biologics, Active Pharma Ingredients, Tablet, Capsule, Parenteral, Oral Liquid), End User (Big Pharma, Small Pharma, Generic Pharma, CRO) - Global Forecast to 2024

 

出版社 出版年月電子版価格 ページ数図表数
MarketsandMarkets
マーケッツアンドマーケッツ
2019年8月US$4,950
シングルユーザライセンス
187 156

サマリー

幅広い市場に関する調査レポートを出版しているマーケッツアンドマーケッツ(MarketsandMarkets)の医薬品受託開発・製造市場に関する調査レポートです。

“The global pharmaceutical contract development and manufacturing market is projected to grow at a CAGR of 7.1%.”

The pharmaceutical contract development and manufacturing market is expected to reach USD 126.6 billion by 2024 from an estimated USD 90.0 billion in 2019, at a CAGR of 7.1%. The rising demand for generics, increasing investments in pharmaceutical R&D, and investments in advanced manufacturing technologies by CDMOs are the primary growth factors for this market. The increasing demand for biological therapies, growing focus on specialty medicines, growth in the nuclear medicines sector, and advancements in cell and gene therapies are expected to offer significant growth opportunities for players in this market. However, the introduction of serialization and changing trade policies between countries are major market challenges.

“The biologics manufacturing segment is expected to grow at the highest rate during the forecast period.”

On the basis of service, the pharmaceutical contract development and manufacturing market is segmented into pharmaceutical manufacturing, biologics manufacturing, and drug development services. The biologics manufacturing segment is projected to witness the highest growth in the pharmaceutical contract development and manufacturing market during the forecast period. Growth in this segment is largely driven by the growing generics market and the impending patent cliff in the pharmaceuticals industry, which have propelled interest toward biologics.

“The big pharma end user segment is expected to account for the largest market share in 2019.”

The big pharma end-user segment holds the largest share of the pharmaceutical contract development and manufacturing market. The emergence of new medicines and therapy forms, pricing pressure, pipeline challenges, and growing opportunities in emerging markets are factors contributing to the larger share of this segment.

“The Asia Pacific is likely to be the fastest-growing market for players operating in the pharmaceutical contract development and manufacturing market.”

Although Europe accounted for the largest share of the global pharmaceutical contract development and manufacturing market in 2018, the Asia Pacific is expected to witness the highest CAGR during the forecast period. The growth of its manufacturing sector, favorable government regulations, expansions by leading companies, increasing emphasis on off-patent drugs, and its highly skilled workforce are factors driving the growth of this regional segment.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1 (21%), Tier 2 (26%), and Tier 3 (53%)
• By Designation: C-level (32%), Director-level (26%), and Others (42%)
• By Region: North America (35%), Europe (30%), Asia Pacific (15%), Latin America (10%), and the Middle East & Africa (10%)

The prominent players in the pharmaceutical contract development and manufacturing market include Thermo Fisher Scientific (US), Catalent (US), Lonza Group Ltd (Switzerland), Recipharm AB (Sweden), Vetter Pharma International GMBH (Germany), FAMAR Health Care Services (Greece), AbbVie (US), Aenova Group (Germany), Consort Medical plc (UK), Almac Group (UK), and Siegfried Holding AG (Switzerland).

Research Coverage:

This report analyzes the market for various pharmaceutical contract development and manufacturing services and their adoption patterns. It aims at estimating the market size and future growth potential of the global pharmaceutical contract development and manufacturing market and its service, end user, and regional segments. The report also includes an in-depth competitive analysis of the key players in this market, along with their company profiles, service offerings, and recent developments.

Reasons to Buy the Report

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies for strengthening their market presence.

This report provides insights on the following pointers:

• Market Penetration: Comprehensive information on the service portfolios offered by the top players in the global pharmaceutical contract development and manufacturing market
• Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the global pharmaceutical contract development and manufacturing market
• Market Development: Comprehensive information on the lucrative emerging regions
• Market Diversification: Exhaustive information about new services, growing geographies, and recent developments in the global pharmaceutical contract development and manufacturing market
• Competitive Assessment: In-depth assessment of market ranking, growth strategies, revenue analysis, and services of leading players in the global pharmaceutical contract development and manufacturing market
 



目次

1 INTRODUCTION 18
1.1 OBJECTIVES OF THE STUDY 18
1.2 MARKET DEFINITION 18
1.3 MARKET SCOPE 18
1.3.1 MARKETS COVERED 19
1.3.2 YEARS CONSIDERED FOR THE STUDY 19
1.4 CURRENCY 20
1.5 LIMITATIONS 20
1.6 STAKEHOLDERS 20
2 RESEARCH METHODOLOGY 21
2.1 RESEARCH APPROACH 21
2.1.1 SECONDARY RESEARCH 22
2.1.1.1 Key data from secondary sources 22
2.1.2 PRIMARY RESEARCH 23
2.1.2.1 Key data from primary sources 23
2.1.2.2 Breakdown of primaries 24
2.1.2.3 Key industry insights 24
2.2 MARKET SIZE ESTIMATION 25
2.3 DATA TRIANGULATION APPROACH 26
2.4 MARKET PLAYERS RANKING ANALYSIS 27
2.5 ASSUMPTIONS FOR THE STUDY 27
3 EXECUTIVE SUMMARY 28
4 PREMIUM INSIGHTS 32
4.1 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING: MARKET OVERVIEW 32
4.2 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 33
4.3 REGIONAL MIX: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET (2019–2024) 34
4.4 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DEVELOPED VS. DEVELOPING MARKETS, 2019 VS. 2024 35

5 MARKET OVERVIEW 36
5.1 INTRODUCTION 36
5.2 MARKET DYNAMICS 36
5.2.1 DRIVERS 37
5.2.1.1 Growing demand for generics 37
5.2.1.2 Increasing investments in pharmaceutical R&D 38
5.2.1.3 Investments in advanced manufacturing technologies by CDMOs 39
5.2.2 OPPORTUNITIES 40
5.2.2.1 Increasing demand for biological therapies 40
5.2.2.2 Growing focus on specialty medicines 41
5.2.2.3 Growth in the nuclear medicine sector 41
5.2.2.4 Growing demand for cell and gene therapies 42
5.2.3 CHALLENGES 42
5.2.3.1 Introduction of serialization 42
5.2.3.2 Changing trade policies between countries 43
5.2.4 TRENDS 43
5.2.4.1 Increasing CDMO manufacturing footprint in Asian countries 43
5.2.4.2 CDMO industry consolidation 44
5.2.4.3 Increasing outsourcing of clinical trials to emerging markets 45
6 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE 46
6.1 INTRODUCTION 47
6.2 PHARMACEUTICAL MANUFACTURING SERVICES 48
6.2.1 PHARMACEUTICAL API MANUFACTURING SERVICES 50
6.2.1.1 Need to cut costs and ensure focus on core areas leads companies to outsource API manufacturing 50
6.2.2 PHARMACEUTICAL FDF MANUFACTURING SERVICES 51
6.2.2.1 Parenteral/injectable manufacturing services 54
6.2.2.1.1 Need for high levels of expertise and growing drug development activity are driving the demand for contract manufacturing 54
6.2.2.2 Tablet manufacturing services 56
6.2.2.2.1 Shifting manufacturing requirements and need to streamline production processes is driving market growth 56
6.2.2.3 Capsule manufacturing services 57
6.2.2.3.1 Growth in demand for capsule formulations has ensured growth opportunities for service providers 57
6.2.2.4 Oral liquid manufacturing services 59
6.2.2.4.1 Complexities involved in oral liquid manufacturing have prompted companies to look to outsourcing 59
6.2.2.5 Other formulations 60

6.3 DRUG DEVELOPMENT SERVICES 62
6.3.1 DRUG SUBSTANCE COMPLEXITY AND HIGH COSTS HAVE SUPPORTED THE OUTSOURCING OF DRUG DEVELOPMENT 62
6.4 BIOLOGICS MANUFACTURING SERVICES 63
6.4.1 BIOLOGICS API MANUFACTURING SERVICES 65
6.4.1.1 The market for biologics API manufacturing is still in the emergent phase 65
6.4.2 BIOLOGICS FDF MANUFACTURING SERVICES 66
6.4.2.1 Increasing R&D costs and process complexity have prompted the shift toward contract manufacturing 66
7 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER 68
7.1 INTRODUCTION 69
7.2 BIG PHARMA 70
7.2.1 EMERGENCE OF NEW MEDICINES AND THERAPY FORMS TO CONTRIBUTE TO THE GROWTH OF THIS MARKET 70
7.3 SMALL & MID-SIZE PHARMA 71
7.3.1 GROWING DEVELOPMENT OF BIOLOGIC DRUGS AND HIGH PRICING PRESSURE TO BOOST MARKET GROWTH 71
7.4 GENERIC PHARMACEUTICAL COMPANIES 73
7.4.1 GROWING DEMAND FOR GENERICS TO SUPPORT MARKET GROWTH 73
7.5 OTHER END USERS 74
8 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY REGION 76
8.1 INTRODUCTION 77
8.2 EUROPE 78
8.2.1 ITALY 82
8.2.1.1 Increasing focus on clinical research and the growing popularity of branded drugs are driving the demand for contract development and manufacturing 82
8.2.2 GERMANY 85
8.2.2.1 High healthcare expenditure and increased pharmaceutical production to support market growth 85
8.2.3 FRANCE 87
8.2.3.1 Presence of leading pharmaceutical companies to support market growth in France 87
8.2.4 UK 90
8.2.4.1 Growth in the generics market and the rising cost of manufacturing parenteral formulations are driving market growth 90
8.2.5 SWITZERLAND 93
8.2.5.1 Large volume of pharmaceutical production and growing scope for generics is expected to growth opportunities 93

8.2.6 SPAIN 95
8.2.6.1 Increase in biologics production to support market growth 95
8.2.7 REST OF EUROPE 98
8.3 NORTH AMERICA 100
8.3.1 US 104
8.3.1.1 The US dominates the North American pharmaceutical contract development and manufacturing market 104
8.3.2 CANADA 106
8.3.2.1 Growth of the emerging markets and slowdown in new product approvals will hamper market growth 106
8.4 ASIA PACIFIC 109
8.4.1 INDIA 113
8.4.1.1 Low manufacturing costs and a skilled workforce are factors attracting outsourcing and investment to India 113
8.4.2 CHINA 116
8.4.2.1 Favorable government regulations are fueling market growth in China 116
8.4.3 JAPAN 119
8.4.3.1 Growing generics demand and push from the government will drive the demand for contract manufacturing of drugs 119
8.4.4 REST OF ASIA PACIFIC 122
8.5 LATIN AMERICA 125
8.5.1 FAVORABLE COST STRUCTURE AND GOVERNMENT INVESTMENTS TO DRIVE PHARMACEUTICAL PRODUCTION IN LATAM 125
8.6 MIDDLE EAST & AFRICA 128
8.6.1 GOVERNMENT SUPPORT TO BOOST LOCAL PRODUCTION IS EXPECTED TO OFFER GROWTH OPPORTUNITIES FOR THE CONTRACT MANUFACTURERS IN THE REGION 128
9 COMPETITIVE LANDSCAPE 132
9.1 OVERVIEW 132
9.2 MARKET RANKING 133
9.2.1 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY KEY PLAYERS, 2018 133
9.3 COMPETITIVE LEADERSHIP MAPPING 135
9.3.1 VISIONARY LEADERS 135
9.3.2 INNOVATORS 135
9.3.3 DYNAMIC DIFFERENTIATORS 136
9.3.4 EMERGING COMPANIES 136
9.4 COMPETITIVE SITUATION AND TRENDS 137
9.4.1 PRODUCT LAUNCHES 137
9.4.2 EXPANSIONS 137
9.4.3 ACQUISITIONS 138
9.4.4 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS 140

10 COMPANY PROFILES 142
(Business Overview, Products Offered, Recent Developments, MnM View)*
10.1 THERMO FISHER SCIENTIFIC INC. 142
10.2 CATALENT, INC. 146
10.3 LONZA GROUP LTD 151
10.4 RECIPHARM AB 156
10.5 VETTER PHARMA INTERNATIONAL GMBH 161
10.6 FAMAR HEALTH CARE SERVICES 162
10.7 ABBVIE INC. 164
10.8 AENOVA GROUP 167
10.9 CONSORT MEDICAL PLC 168
10.10 ALMAC GROUP 170
10.11 SIEGFRIED HOLDING AG 171
10.12 EVONIK INDUSTRIES AG 174
10.13 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 176
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
11 APPENDIX 179
11.1 INSIGHTS OF INDUSTRY EXPERTS 179
11.2 DISCUSSION GUIDE 180
11.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 183
11.4 AVAILABLE CUSTOMIZATIONS 185
11.5 RELATED REPORTS 185
11.6 AUTHOR DETAILS 186

 

LIST OF TABLES

TABLE 1 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET,
BY SERVICE, 2017–2024 (USD MILLION) 47
TABLE 2 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE,
2017–2024 (USD MILLION) 48
TABLE 3 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY,
2017–2024 (USD MILLION) 49
TABLE 4 PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY,
2017–2024 (USD MILLION) 51
TABLE 5 PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE,
2017–2024 (USD MILLION) 52
TABLE 6 PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 53
TABLE 7 PARENTERAL/INJECTABLE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 55
TABLE 8 TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY,
2017–2024 (USD MILLION) 57
TABLE 9 CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY,
2017–2024 (USD MILLION) 58
TABLE 10 ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY,
2017–2024 (USD MILLION) 59
TABLE 11 OTHER FORMULATION MANUFACTURING SERVICES MARKET, BY COUNTRY,
2017–2024 (USD MILLION) 61
TABLE 12 DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY,
2017–2024 (USD MILLION) 63
TABLE 13 BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2017–2024 (USD MILLION) 64
TABLE 14 BIOLOGICS MANUFACTURING SERVICES MARKET, BY COUNTRY,
2017–2024 (USD MILLION) 65
TABLE 15 BIOLOGICS API MANUFACTURING SERVICES MARKET, BY COUNTRY,
2017–2024 (USD MILLION) 66
TABLE 16 BIOLOGICS FINISHED DOSAGE FORMULATIONS MARKET, BY COUNTRY,
2017–2024 (USD MILLION) 67
TABLE 17 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET,
BY END USER, 2017–2024 (USD MILLION) 69
TABLE 18 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR BIG PHARMA, BY COUNTRY, 2017–2024 (USD MILLION) 71
TABLE 19 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR SMALL & MID-SIZE PHARMA, BY COUNTRY, 2017–2024 (USD MILLION) 72
TABLE 20 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY,
2017–2024 (USD MILLION) 74
TABLE 21 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
FOR OTHER END USERS, BY COUNTRY, 2017–2024 (USD MILLION) 75
TABLE 22 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET,
BY REGION, 2017–2024 (USD MILLION) 78
TABLE 23 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 80
TABLE 24 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION) 80
TABLE 25 EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION) 81
TABLE 26 EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION) 81
TABLE 27 EUROPE: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2017–2024 (USD MILLION) 81
TABLE 28 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION) 82
TABLE 29 ITALY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION) 83
TABLE 30 ITALY: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE,
2017–2024 (USD MILLION) 83
TABLE 31 ITALY: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 84
TABLE 32 ITALY: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2017–2024 (USD MILLION) 84
TABLE 33 ITALY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION) 84
TABLE 34 GERMANY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION) 86
TABLE 35 GERMANY: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION) 86
TABLE 36 GERMANY: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION) 86
TABLE 37 GERMANY: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2017–2024 (USD MILLION) 87
TABLE 38 GERMANY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION) 87
TABLE 39 FRANCE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION) 88
TABLE 40 FRANCE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 89
TABLE 41 FRANCE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 89
TABLE 42 FRANCE: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2017–2024 (USD MILLION) 89
TABLE 43 FRANCE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION) 90
TABLE 44 UK: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION) 91
TABLE 45 UK: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE,
2017–2024 (USD MILLION) 91
TABLE 46 UK: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE,
2017–2024 (USD MILLION) 92
TABLE 47 UK: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2017–2024 (USD MILLION) 92
TABLE 48 UK: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION) 92
TABLE 49 SWITZERLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION) 93
TABLE 50 SWITZERLAND: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION) 94
TABLE 51 SWITZERLAND: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 94
TABLE 52 SWITZERLAND: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2017–2024 (USD MILLION) 95
TABLE 53 SWITZERLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION) 95
TABLE 54 SPAIN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION) 96
TABLE 55 SPAIN: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE,
2017–2024 (USD MILLION) 96
TABLE 56 SPAIN: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION) 97
TABLE 57 SPAIN: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2017–2024 (USD MILLION) 97
TABLE 58 SPAIN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION) 97
TABLE 59 ROE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION) 98
TABLE 60 ROE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE,
2017–2024 (USD MILLION) 99
TABLE 61 ROE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION) 99
TABLE 62 ROE: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2017–2024 (USD MILLION) 99
TABLE 63 ROE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION) 100
TABLE 64 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 102
TABLE 65 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION) 102
TABLE 66 NORTH AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 102
TABLE 67 NORTH AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 103
TABLE 68 NORTH AMERICA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION) 103
TABLE 69 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION) 103
TABLE 70 US: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION) 105
TABLE 71 US: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE,
2017–2024 (USD MILLION) 105
TABLE 72 US: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE,
2017–2024 (USD MILLION) 105
TABLE 73 US: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2017–2024 (USD MILLION) 106
TABLE 74 US: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION) 106
TABLE 75 CANADA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION) 107
TABLE 76 CANADA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION) 108
TABLE 77 CANADA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 108
TABLE 78 CANADA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2017–2024 (USD MILLION) 108
TABLE 79 CANADA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION) 109
TABLE 80 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 111
TABLE 81 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION) 111
TABLE 82 ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 111
TABLE 83 ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 112
TABLE 84 ASIA PACIFIC: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2017–2024 (USD MILLION) 112
TABLE 85 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION) 113
TABLE 86 INDIA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION) 114
TABLE 87 INDIA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE,
2017–2024 (USD MILLION) 114
TABLE 88 INDIA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION) 115
TABLE 89 INDIA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2017–2024 (USD MILLION) 115
TABLE 90 INDIA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION) 115
TABLE 91 CHINA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION) 117
TABLE 92 CHINA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE,
2017–2024 (USD MILLION) 117
TABLE 93 CHINA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION) 118
TABLE 94 CHINA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2017–2024 (USD MILLION) 118
TABLE 95 CHINA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION) 118
TABLE 96 JAPAN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION) 120
TABLE 97 JAPAN: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE,
2017–2024 (USD MILLION) 120
TABLE 98 JAPAN: FDF MANUFACTURING SERVICES MARKET, BY TYPE,
2017–2024 (USD MILLION) 121
TABLE 99 JAPAN: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2017–2024 (USD MILLION) 121
TABLE 100 JAPAN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION) 121
TABLE 101 ROAPAC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION) 123
TABLE 102 ROAPAC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION) 123
TABLE 103 ROAPAC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 124
TABLE 104 ROAPAC: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2017–2024 (USD MILLION) 124
TABLE 105 ROAPAC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION) 125
TABLE 106 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION) 126
TABLE 107 LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 126
TABLE 108 LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 127
TABLE 109 LATIN AMERICA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION) 127
TABLE 110 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION) 128
TABLE 111 MIDDLE EAST & AFRICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2024 (USD MILLION) 129
TABLE 112 MIDDLE EAST & AFRICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION) 129
TABLE 113 MIDDLE EAST & AFRICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION) 130
TABLE 114 MIDDLE EAST & AFRICA: BIOLOGICS MANUFACTURING SERVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 130
TABLE 115 MIDDLE EAST & AFRICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2024 (USD MILLION) 131
TABLE 116 PRODUCT LAUNCHES, 2016–2019 137
TABLE 117 EXPANSIONS, 2016–2019 137
TABLE 118 ACQUISITIONS, 2016–2019 138
TABLE 119 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS 2016–2019 140

 

LIST OF FIGURES

FIGURE 1 RESEARCH DESIGN 21
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATIONS,
AND REGION 24
FIGURE 3 BOTTOM-UP APPROACH 25
FIGURE 4 TOP-DOWN APPROACH 25
FIGURE 5 DATA TRIANGULATION METHODOLOGY 26
FIGURE 6 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET,
BY SERVICE, 2019 VS. 2024 (USD BILLION) 28
FIGURE 7 BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2019 VS. 2024 (USD BILLION) 29
FIGURE 8 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET,
BY END USER, 2019 VS. 2024 (USD BILLION) 29
FIGURE 9 GEOGRAPHICAL SNAPSHOT OF THE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET 30
FIGURE 10 GROWING DEMAND FOR GENERICS IS ONE OF THE KEY FACTORS DRIVING MARKET GROWTH 32
FIGURE 11 INDIA IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING
THE FORECAST PERIOD 33
FIGURE 12 ASIA PACIFIC TO GROW AT THE HIGHEST RATE DURING THE FORECAST
PERIOD (2019–2024) 34
FIGURE 13 DEVELOPING MARKETS TO REGISTER A HIGHER GROWTH RATE BETWEEN
2019 & 2024 35
FIGURE 14 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DRIVERS, OPPORTUNITIES, CHALLENGES, AND TRENDS 36
FIGURE 15 GROWTH OF THE GENERICS MARKET (2006 VS. 2016) 37
FIGURE 16 NUMBER OF PHARMA COMPANIES WITH ACTIVE DRUG PIPELINE PROJECTS (2010–2017) 38
FIGURE 17 GLOBAL LIFE SCIENCE R&D SPENDING (2016–2018) 38
FIGURE 18 CDMO MERGER AND ACQUISITION VOLUME AND VALUE (2012–2016) 44
FIGURE 19 TOP CONSOLIDATORS (2012–2018) 44
FIGURE 20 PHARMACEUTICAL MANUFACTURING SERVICES SEGMENT TO DOMINATE THE SERVICES MARKET DURING THE FORECAST PERIOD 47
FIGURE 21 BIG PHARMA FORMED THE LARGEST END USER SEGMENT IN THE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET 69
FIGURE 22 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: GEOGRAPHICAL SNAPSHOT 77
FIGURE 23 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SNAPSHOT 79
FIGURE 24 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SNAPSHOT 101
FIGURE 25 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SNAPSHOT 110
FIGURE 26 KEY GROWTH STRATEGIES ADOPTED BY MARKET PLAYERS FROM JANUARY
2016 TO JULY 2019 132
FIGURE 27 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET RANKING, BY KEY PLAYER, 2018 133
FIGURE 28 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: (GLOBAL) COMPETITIVE LEADERSHIP MAPPING (2018) 136
FIGURE 29 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2018) 143
FIGURE 30 CATALENT, INC.: COMPANY SNAPSHOT (2018) 146
FIGURE 31 LONZA GROUP LTD: COMPANY SNAPSHOT (2018) 151
FIGURE 32 RECIPHARM AB: COMPANY SNAPSHOT (2018) 157
FIGURE 33 ABBVIE INC.: COMPANY SNAPSHOT (2018) 164
FIGURE 34 CONSORT MEDICAL PLC: COMPANY SNAPSHOT (2018) 168
FIGURE 35 SIEGFRIED HOLDING AG: COMPANY SNAPSHOT (2018) 171
FIGURE 36 EVONIK INDUSTRIES AG: COMPANY SNAPSHOT (2018) 174
FIGURE 37 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2018) 176
 

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る